---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Heterogeneity of treatment effect"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Heterogeneity of treatment effect. Topics: Barzolvolimab phase 2: efficacy at Week 12 and Week 52 by baseline total IgE; Barzolvolimab phase 2: Week 12 response with and without prior omalizumab; Barzolvolimab phase 3: complete response (UAS7=0) at Week 12, overall and in omalizumab-refractory participants; Barzolvolimab phase 2: efficacy by baseline serum tryptase; 10 further topics. 14 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Barzolvolimab phase 2: efficacy at Week 12 and Week 52 by baseline total IgE

> “Barzolvolimab treatment demonstrated rapid and strong efficacy in a Phase 2 study in CSU and was well tolerated.”
> “Patients receiving placebo, or barzolvolimab at 150 mg Q4W or 300 mg Q8W were subgrouped according to baseline IgE levels as previously defined”
> “Analysis was conducted in patients with observable data Weeks 12 and 52.”
> “Similarly strong efficacy was observed in patients with normal/high (≥ 40 IU/mL) or low (< 40 IU/mL) IgE levels for both dosing regimens”
> “Adjusted p-value was non-significant for all comparisons between normal/high vs IgE low subgroups in indicated analyses.”
> “The rate ratio (95% CI) of achieving a complete response in patients with low compared to normal/high baseline IgE was 1.37 (0.74-2.55) and 1.24 (0.71-2.16) in the 150 mg Q4W and 300 mg Q8W groups, respectively.”

Source: [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)

<a id="topic-2.2.2.3-2"></a>

### Barzolvolimab phase 2: Week 12 response with and without prior omalizumab

> “Adults with antihistamine-refractory CSU (urticaria activity score over 7 days [UAS7] ≥ 16) in a phase 2 double-blind placebo-controlled trial were randomized 1:1:1:1”
> “The disease of patients with and without prior omalizumab treatment responded similarly.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

> “Barzolvolimab demonstrated strong improvement in UAS7 independent of omalizumab status at Week 12. Approximately 20% (n=41) of enrolled patients received prior treatment with omalizumab and more than half of these patients had omalizumab-refractory disease. These patients experienced a similar clinical benefit as the overall treated population within their individual dosing groups consistent with the barzolvolimab mechanism of action.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.2.2.3-3"></a>

### Barzolvolimab phase 3: complete response (UAS7=0) at Week 12, overall and in omalizumab-refractory participants

> “Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Population and arm, Week 12 | EMBARQ-CSU1 | EMBARQ-CSU2 |
| --- | --- | --- |
| Overall, placebo | “9.3%” | “12.6%” |
| Overall, 150 mg Q4W | “42.4% (p<.00001)” | “45.7% (p<.00001)” |
| Overall, 300 mg Q8W | “42.1% (p<.00001)” | “44.0% (p<.00001)” |
| Omalizumab-refractory, placebo | “9.3%” | “15.1%” |
| Omalizumab-refractory, 150 mg Q4W | “55.3% (p<.00001)” | “41.7% (p=.0089)” |
| Omalizumab-refractory, 300 mg Q8W | “44.3% (p=.00017)” | “46.4% (p=.0036)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “P-values are based on adjusted odds ratio of logistic regression models.”
> “A higher proportion of patients achieved Complete Response (UAS7=0) vs placebo at Week 12 in the sub-population of patients with CSU refractory to omalizumab.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Patients treated with omalizumab at approved doses for at least 3 months and whose symptoms never responded or who responded initially but symptoms subsequently returned, or who discontinued omalizumab due to intolerance”
> “Adjusted proportions are based on logistic regression model with multiple imputation method.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.2.2.3-4"></a>

### Barzolvolimab phase 2: efficacy by baseline serum tryptase

> “In a Phase 2 study in patients with H1-antihistamine-refractory CSU (NCT05368285)”
> “Baseline serum tryptase was not associated with baseline disease severity nor was predictive of barzolvolimab response”
> “Barzolvolimab demonstrated clinical benefits for patients with CSU regardless of their baseline serum tryptase levels”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="topic-2.2.2.3-5"></a>

### International guideline: biomarkers of response to omalizumab, dupilumab, ciclosporin, and antihistamines

> “In patients under specialist care, additional tests, such as total IgE and IgG-anti-TPO may be performed, as they indicate the likelihood of response to omalizumab”
> “Despite the established statistical association, the diagnostic performance and predictive accuracy of these tests remains limited”
> “Available data shows efficacy regardless of low baseline IgE levels for dupilumab, which is different compared to omalizumab where very low IgE values are often a reason for insufficient response”
> “Ciclosporin can be especially effective in selected patients with CSUaiTIIb with low total IgE levels and other markers of autoimmunity”
> “For example, the presence of concomitant CIndU, high disease activity, elevated CRP and/or the presence of angioedema are indicative for a prolonged duration of CSU and suboptimal response to antihistamine treatment”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.3-6"></a>

### Systematic review of predictors of response to antihistamines, omalizumab, and cyclosporine

> “A systematic search was performed by two independent researchers using the MEDLINE/PubMed database with specific keywords and 73 studies included in the review.”
> “High disease activity, high levels of C-reactive protein and D-dimer are robust predictors for a poor or no response to sgAHs.”
> “Poor or no response to omalizumab is robustly predicted by low serum levels of total IgE.”
> “A good response to cyclosporine is robustly predicted by a positive basophil histamine release assay, whereas low total IgE is an emerging predictor.”

Source: [Fok et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33539587/)

<a id="topic-2.2.2.3-7"></a>

### Omalizumab: response by baseline total IgE and its change after 4 weeks

> “Total IgE levels were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE).”
> “Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032).”
> “Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ratios, significantly better than by bIgE levels (P = .016).”

Source: [Ertas et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29083482/)

<a id="topic-2.2.2.3-8"></a>

### Type IIb autoimmune endotype: low total IgE and poor response to antihistamines and omalizumab

> “Type IIb autoimmune CSU is mediated by autoantibodies that activate mast cells, for example, via IgE and FcεRI, and is present in less than 10% of patients with CSU when strict criteria are used, that is, triple positivity of autologous serum skin test, immunoassays for IgG autoantibodies, and basophil activation tests.”
> “Type IIb autoimmune CSU is characterized by higher disease severity, concomitant autoimmune diseases, low levels of total IgE, elevated levels of IgG-anti-thyroid peroxidase, basopenia, eosinopenia, poor response to antihistamines and to omalizumab, and a good response to cyclosporine.”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="topic-2.2.2.3-9"></a>

### Dupilumab: response by baseline total IgE in omalizumab-naive participants

> “Dupilumab treatment improved ISS7, UAS7, and HSS7 over 12 and 24 weeks, regardless of baseline serum IgE level (interaction p ≥ 0.59 for all treatment by subgroup comparisons)”
> “In the current analysis, baseline total IgE had no predictive value as a dupilumab treatment response biomarker in CSU.”
> “Dupilumab is an effective treatment in H1-antihistamine (H1-AH)-resistant, omalizumab-naïve patients with CSU, regardless of their baseline serum total IgE levels.”

Source: [Maurer et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11393262/)

<a id="topic-2.2.2.3-10"></a>

### Dupilumab: label statements on baseline IgE and on anti-IgE inadequate responders

> “Improvements in ISS7 and UAS7 at Week 24 were consistent regardless of the patients’ baseline IgE level.”
> “CUPID Study B enrolled 108 adult and pediatric patients 12 years of age and older with CSU who were inadequate responders (N=104) to H1 antihistamines and anti-IgE treatments or intolerant (N=4) to anti-IgE therapy.”
> “The DUPIXENT group in CUPID Study B did not meet statistical significance for reduction in the primary endpoint ISS7 at Week 24.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.3-11"></a>

### Remibrutinib and dupilumab by prior biologic or omalizumab exposure

> “Dupilumab, a monoclonal antibody that blocks IL-4Ra, significantly reduced urticaria activity in omalizumab-naive patients and showed smaller effects in patients who were omalizumab-intolerant/incomplete responders”
> “Remibrutinib, a Bruton's tyrosine kinase inhibitor, has shown efficacy in reducing disease symptoms in patients remaining symptomatic despite treatment with sgH1-AH in clinical trials, without a notable drop in efficacy in biologic-experienced patients”

Source: [Kolkhir et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466147/)

<a id="topic-2.2.2.3-12"></a>

### Cyclosporine: candidate predictors of response, systematic review

> “Our systematic review showed that positive autologous serum skin test results, positive baseline basophil histamine release assays, positive baseline basophil activation test responses, elevated baseline plasma D-dimer levels, elevated baseline serum interleukin (IL)-2, IL-5, and tumor necrosis factor-alpha (TNF-α) levels, and low baseline serum IgE levels might assist in predicting favorable CsA responses in CSU patients.”
> “Since most positive results were from non-RCT articles and some data were still inconsistent, this systematic review identified no reliable practical biomarker for predicting CsA treatment response in patients with CSU.”

Source: [Kulthanan et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658402/)

<a id="topic-2.2.2.3-13"></a>

### Comparative network meta-analysis: consistency across age groups and baseline severity

> “Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.”
> “Findings were consistent across age groups and baseline severity, and were robust to subgroup analyses.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.2.2.3-14"></a>

### Sex: poorer urticaria control in women across treatment categories, CURE registry

> “Specifically, a higher number of females had UCT < 12 compared to males when treated with standard-dose second-generation anti-histamines (sgAH; 70.5% vs. 66.9%, p = 0.02), high-dose sgAH (76.5% vs. 73.9%, p = 0.02), omalizumab (53% vs. 44.5%, p = 0.03) and cyclosporine (81% vs. 71.4%, p = 0.02; Table 4).”
> “We analysed Chronic Urticaria Registry (CURE) data, an international real-world registry for patients with chronic urticaria.”

Source: [Kocatürk et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12723574/)

Additional sources: [Gericke et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27838346/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
